Literature DB >> 21107765

B-cell-targeted therapy for the fibrotic complications of systemic sclerosis.

Robert Woodrick1, John Varga.   

Abstract

Entities:  

Year:  2011        PMID： 21107765     DOI： 10.1007/s11926-010-0150-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  15 in total

1.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Authors:  Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard A Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd-Rüdiger Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Journal:  Arthritis Rheum       Date:  2006-09

Review 2.  B-cell targeting in rheumatoid arthritis and other autoimmune diseases.

Authors:  Jonathan C W Edwards; Geraldine Cambridge
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 3.  B cells move to centre stage: novel opportunities for autoimmune disease treatment.

Authors:  Jeffrey L Browning
Journal:  Nat Rev Drug Discov       Date:  2006-07       Impact factor: 84.694

Review 4.  Rituximab: ongoing and future clinical development.

Authors:  Antonio J Grillo-López; Eric Hedrick; Michelle Rashford; Mark Benyunes
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

5.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors:  Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal:  Arthritis Rheum       Date:  2006-05

6.  Does immunological tolerance explain the waste in the B-lymphocyte immune system? Experiment and theory.

Authors:  D Nemazee
Journal:  Ann N Y Acad Sci       Date:  1995-09-29       Impact factor: 5.691

7.  Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.

Authors:  Qian Gong; Qinglin Ou; Shiming Ye; Wyne P Lee; Jennine Cornelius; Lauri Diehl; Wei Yu Lin; Zhilan Hu; Yanmei Lu; Yongmei Chen; Yan Wu; Y Gloria Meng; Peter Gribling; Zhonghua Lin; Kathy Nguyen; Thanhvien Tran; Yifan Zhang; Hugh Rosen; Flavius Martin; Andrew C Chan
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

8.  Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.

Authors:  P P Tak; R M Thurlings; C Rossier; I Nestorov; A Dimic; V Mircetic; M Rischmueller; E Nasonov; E Shmidt; P Emery; A Munafo
Journal:  Arthritis Rheum       Date:  2008-01

Review 9.  Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.

Authors:  Thomas Dörner; Nils Kinnman; Paul P Tak
Journal:  Pharmacol Ther       Date:  2010-01-25       Impact factor: 12.310

10.  CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.

Authors:  Ayumi Yoshizaki; Yohei Iwata; Kazuhiro Komura; Fumihide Ogawa; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.